Processa pharmaceuticals announces first patient dosed in its randomized double-blind, placebo-controlled clinical trial to evaluate pcs499 in treating ulcerations in patients who have necrobiosis lipoidica

~ processa's trial is currently enrolling patients with ulcerated necrobiosis lipoidica . detailed information on the trial can be located on clinicaltrials.gov nct#: 04800562 .~

PCSA Ratings Summary

PCSA Quant Ranking